Lewes, DE -- (SBWIRE) -- 12/13/2016 -- Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing
- BCMA,
- CD123 and
- CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:
- Fc-Engineered Antibodies;
- Radioimmunotherapy;
- Immunotoxins;
- Antibody-Drug Conjugates;
- T-Cell Redirecting Bispecific Antibodies;
- Chimeric Antigen Receptor (CAR) T-Cells.
- The reports describe and discuss

Target background, scientific rationale & expression profiles;
- Preclinical proof-of-concept;
- Clinical experience;
- Competitive landscape;
- Drug or cell therapy profiles;
- Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:
- B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
- CD123: a paradigmatic target for immunotherapeutic treatment modalities
- CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Tables of Content

Report 1:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape

Drug & Cell Therapy Candidate Profiles
CAR T-Cells
Antibody-Drug Conjugate (ADC)
T-Cell Redirecting Antibodies
Company Profiles
References

Report 2:
CD123: a paradigmatic target for immunotherapeutic treatment modalities

Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:

Immunotoxins
Naked Antibody
Fc-Engineered Antibodies
Antibody-Drug Conjugates
T-Cell Redirecting Bispecific Antibodies
Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

Report 3:
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics

Naked antibodies;
Radioimmunotherapy (RIT);
Immunotoxins (IT);
Antibody-Dug Conjugates (ADC); and
Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics

For more information Visit at: http://www.marketresearchreports.com/la-merie-publishing/report-package-hot-targets-empowered-antibody-and-cell-therapy-technologies

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions